BioSpace News Archive

The third time is the charm for AstraZeneca and its hyperkalemia treatment that has been dogged by manufacturing issues. After multiple rejections, the U.S. Food and Drug Administration finally gave its approval for the treatment.

Biopharma is big business and anyone who doubts that—unlikely—only needs to look at the revenue figures of the top drugs.

There are several companies facing decisions by the U.S. Food and Drug Administration (FDA) this upcoming week. However, it should be noted that because the upcoming weekend is the Memorial Day holiday in the United States, some of these decisions may be made before their dates to avoid the holiday. Here’s a look.

As another HIV Vaccine Awareness Day slides by on the calendar, there is still no cure for the disease. However, many pharma and biotech companies are desperately working on developing therapeutics for the devastating disease.

This weekend GSK unveiled long-term data that showed that one-third of patients treated with Nucala (mepolizumab) experienced no asthma-related exacerbations during the study.

Nabriva Therapeutics reported positive topline results from its Phase III clinical trial of oral lefamulin compared to oral moxifloxacin in adults with moderate community-acquired bacterial pneumonia (CABP).

Avenue Therapeutics, announced its Phase III clinical trial of IV tramadol hit its primary endpoint of statistically significant improvement.

Genentech’s hemophilia treatment Hemlibra continues to demonstrate its efficacy in treating patients. New late-stage data presented at World Federation of Hemophilia 2018 World Congress shows the drug significantly reduced treated bleeds in a broad patient population in two separate studies.

Prime Minister Theresa May continues to push for growth in the United Kingdom’s pharma sector. Today she called for expanding the role of artificial intelligence in the diagnosis process for cancer.

Rain Therapeutics, headquartered in Fremont, California, closed on a tranched Series A financing of $18.4 million.